The Company has formulated a policy for determining ‘material’ subsidiaries pursuant to the provisions of the Listing Agreement. The said policy is available at the Company website http://www.jkzddm.com/docs/PolicyDocument_MaterialSubsidiary.pdf
The Company has 8 subsidiaries and 2 step down subsidiaries as on March 31, 2016. Biocon FZ-LLC, a wholly owned subsidiary was incorporated on June 16, 2015 in Dubai. Biocon Biologics Limited, a wholly owned subsidiary was incorporated on March 2, 2016 in the United Kingdom. Biocon Pharma Inc, was incorporated on July 27, 2015 in the United States of America as a wholly owned subsidiary of Biocon Pharma Limited.
fun88 International Limited
fun88 International Limited (“fun88”) is one of India’s leading contract research organisations offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, fun88官网, and biotechnology amongst others. fun88 helps its clients in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, formulation development and stability studies) and pilot manufacturing (scale-up, pre-clinical and clinical supplies) each with distinctive economic advantage. Unlike the traditional business models, these services are offered through flexible business models ranging from a full-time equivalent (“FTE”) to a fee-for-service (“FFS”) model or a combination customized on the client’s specific requirement.
On August 11, 2015 fun88’s shares were listed on the NSE and the BSE after a successful Initial Public Offering (IPO) through an offer for sale by the Company.
Biocon Research Limited
Biocon Research Limited (BRL), a 100% subsidiary of the Company, undertakes discovery and development research work in biologics and provides scientific support for various development programmes of the group.
BRL’s current business is largely directed towards the R&D services for Monoclonal antibody molecules and Proteins (mAbs), insulin Tregopil (formally referred to as IN-105) and other insulin products on behalf of other group companies. The research programs undertaken by BRL have made significant inroads to the next level of global clinical trials. During the year, BRL licensed the ex-India development and commercialisation rights of its existing mAbs portfolio to Biocon Biologics Limited (‘BUK’). BRL continues to hold 0.93% shareholding in fun88.
Biocon Pharma Limited
Biocon Pharma Limited (“BPL”) is a wholly owned subsidiary of the Company. BPL would be engaged in the development and manufacture of generic formulations for
sale in global markets, especially opportunities in US/EU. BPL is in the process of setting up its formulations manufacturing facility for oral solid dosages at Biocon SEZ,
Biocon Academy spearheads Biocon’s CSR initiatives in the technical/professional education segment. The academy was established as a Centre of Excellence for Advanced Learning in Biosciences in 2014. Biocon Academy leverages rich industry experience of Biocon and subject matter expertise of international Education Partners such as Keck Graduate Institute of Claremont, California (USA). The academy is dedicated exclusively to industry oriented biosciences education. The programs offered by
the academy aim to empower the Biotechnology and Engineering graduates with advanced learning and industrial proficiency through job-skills development essential to build a promising career in the Biotech industry.
Biocon SA, a wholly owned subsidiary of the Company, is primarily engaged in the business of development and commercialization of generic recombinant human insulin and its analogues for global markets under various internal as well as partnered programs. Biocon SA also holds the marketing rights for the group’s insulin portfolio.
Biocon SA is also in the business of identifying and developing other novel molecules into commercial products or licensable assets through strategic partnerships.
Biocon SDN. BHD
Biocon SDN. BHD., Malaysia is a step down subsidiary of the Company, wholly owned by BUK. Biocon SDN. BHD. was established with an objective to set up the group’s first overseas manufacturing facility at Malaysia. It is located within BioXcell, a biotechnology park in Nusajaya, Johor, which is being promoted by the Malaysian
Government. The first phase of the facility, designed to manufacture recombinant human insulin and insulin analogs has been commissioned and a series of operational processes - scale up, validation, and stability activities were performed in FY 2015-16. The manufacturing facility received local cGMP certification from the National Pharmaceutical Control Bureau, Malaysia and the plant is currently undergoing a series of validation activities to certify its operational efficiency.
Biocon SDN BHD will seek approvals from leading regulatory agencies across the globe for marketing its products in various RoW during FY’17. Approval from the developed markets are expected in the later years. The Malaysian facility is expected to start commercial operations in the second half of FY17.
NeoBiocon FZ LLC
Neo Biocon FZ LLC (“NeoBiocon”), a 51% owned subsidiary of the Company is a research and marketing pharmaceutical company, which was incorporated in January 2008. Operating out of Dubai and Abu Dhabi, NeoBiocon helps us reach out to the Middle East and GCC with our veritable portfolio of quality small molecule drugs.
Biocon FZ -LLC
Biocon FZ LLC is a wholly owned subsidiary of the Company based in Dubai. Incorporated in June 2015, Biocon FZ LLC has been established as a marketing entity for pharmaceutical products to target markets in the Middle East and GCC.
Biocon Biologics Limited
Biocon Biologics Limited (“BUK”) is a wholly owned subsidiary of the Company. Incorporated in the United Kingdom in March 2016, BUK will house Biocon’s biosimilar biologics business. During the year, BUK acquired the shareholding of Biocon SDN. BHD. from Biocon SA and the Company, making Biocon SDN. BHD. a wholly owned
subsidiary of BUK.
Biocon Pharma Inc.
Biocon Pharma, Inc. (“BPI”) is a wholly owned subsidiary of Biocon Pharma Limited was incorporated in July 2015 in the United States of America. BPI would be engaged in commercialization of generic formulations in the United States.
Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
Biocon's Insulin Glargine Launched in Japan
Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
Biocon's Insulin Glargine Receives Regulatory Approval in Japan
Biocon Announced Data from Key Studies for Insulin Tregopil
Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY17
Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
Biocon's Insulin Glargine Receives Regulatory Approval in Japan
Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
NeoBiocon Partners with Novartis to offer Vildagliptin for Diabetics in UAE
Biocon Foundation Recognized for Outstanding Contribution to Public Health by WHO -India
Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica
Biocon's CRO Arm fun88 Seeks Approval for IPO, Files DRHP; Offer allows Biocon to monetize its shareholding in fun88
Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed
Biocon's Biosimilars Programs Make Progress; One of the Largest Generic Insulin Analogs and Biosimilars Portfolio in Advanced Stages of Development
Biocon's CRO Arm fun88 Lists on BSE and NSE; Valued at $1 billion on Market Debut
Biocon Inaugurates World Class Devices Facility in Bangalore & Introduces Basalog One™ in India
Biocon is the Only Asian Company to be Ranked Among Top 20 Global Biotech Employers for 2015
Biocon and Abraxis BioScience Inc., announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India.
Biocon has been conferred with the Sir J C Bose Memorial Award – 2013 (Institutional category) by Indian Science Monitor (ISM) for its contribution in the field of Biotechnology, with special reference to the launch of ALZUMAb (Itolizumab)
Biocon introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India
fun88, a subsidiary of Biocon Group, in collaboration with Baxter sets up a dedicated Research and Development Center at Biocon Park
Silver Leaf Oak (Mauritius) Limited, an investment vehicle advised by India Value Fund Advisors acquires a minority 10% stake in fun88 International Limited, Biocon's Research Services subsidiary. Silver Leaf will acquire the stake from Biocon Research Limited, a wholly owned subsidiary of Biocon Limited at a valuation of Rs.3800 Crore
Biocon received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis
Biocon enhances Partnership with Mylan through Strategic Collaboration for Insulin Products
Biocon Delivers a Healthy Growth of 22% driven by strong traction in Biopharma
Biocon Launched ALZUMAb™- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India
Biocon Partnered with CytoSorbents to Market CytoSorb® - A 'First-in-Class' Therapy for Sepsis Management
Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine
Biocon Unveils Biocon Academy - A Center of Excellence for Advanced Learning in Applied Biosciences
Biocon & Mylan received Indian Regulatory Approval for Trastuzumab for Treating Breast Cancer
Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics
Biocon's ALZUMAb™ wins BioSpectrum BioPharma Product of the Year, 2013
Biocon Academy's Flagship Program in Collaboration with KGI Takes Off to a Flying Start
Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin
GE Capital invests in fun88, Biocon's Research Services Subsidiary
Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoriasis
fun88 - a subsidiary of Biocon Group, in collaboration with Abbott, setup a dedicated Nutrition Research and Development Center at Biocon Park
Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine
Biocon: the only Asian Company to Feature in the Global Top 20 BioPharma Employers, by Science Magazine
Biocon enters into an agreement with Bristol-Myers Squibb for its IN-105, an Oral Insulin drug
Biocon divests its stake in its German subsidiary, AxiCorp GmbH, to the existing group of promoter shareholders, AxiCorp was the licensee for Biocon's biosimilar Insulin and Glargine in Germany and had the sole responsibility for commercializing these products. As a consequence of this divestment, these rights revert to Biocon.
Biocon announced project commencement for first high-end fun88官网 manufacturing and R&D facility in Bio-XCell, Malaysia
Biocon launched INSUPen®, a convenient and affordable reusable insulin delivery device.
Biocon explores investment in Malaysia in partnership with BiotechCorp
Biocon and Bayer join hands to create awareness for self monitoring for diabetics
fun88 and Endo Pharmaceuticals, USA to jointly discover and develop novel biological drug molecules to fight cancer
Biocon acquires stake of its Cuban partner CIMAB S.A. in their seven year old JV, Biocon fun88官网s Pvt. Ltd
Biocon and Optimer Pharmaceuticals announce manufacturing and supply agreement for a novel API, first-in-class anti-infective (C. difficile)
Biocon and the Center of Molecular Immunology (CIM), based in Havana, Cuba strengthen their existing research partnership by joining forces for an integrated antibody program in immunology
Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp)
Biocon's fun88 partners with Sapient Discovery to expand integrated drug discovery offerings
Biocon's fun88 and DuPont Crop Protection Forge Alliance Partnership
Bristol-Myers Squibb and Biocon's fun88 open new R&D Facility at Biocon Park
Biocon launched BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics
Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management
Biocon announced Strategic Collaboration with Mylan to enter the Global Generic Biologics Market
Biocon Limited and Amylin Pharmaceuticals entered into a Global Development and Commercialization Agreement for a Novel Peptide Hybrid. The Program will focus on the potential treatment of diabetes.
Biocon and HCG group of hospitals join hands to fight against cervical
Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million
Biocon launched a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future.
Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer.
Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).
Biocon is the 7th largest biotech employer in the world (Med Ad News).
Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome.
NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer.
Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of fun88官网s for the GCC countries (Gulf Cooperation Council).
Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR® in Pakistan.
Biocon announced the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.
fun88 enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.
Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore
Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on fun88官网s
Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.
Biocon and Neopharma sign an MoU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.
Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam.
Biocon inaugurates Biocon fun88官网s, India's largest multi-product Biologics facility at Biocon Park
Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.
Biocon announced a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.
fun88 and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.
Biocon launched India's first anti-cancer drug BIOMAb EGFR®.
Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East
Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.
fun88 establishes new research centre
Biocon Limited, announced the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.
Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.
Biocon is the first company worldwide to develop human insulin on a Pichia expression system
Clinigene's clinical laboratory is the first in India to receive CAP accreditation
Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule
Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent
Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals
Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity
Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion
Biocon leverages its technology platform to enter fun88官网s and statins
Biocon establishes fun88 International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector
Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany
Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level
Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International
Biocon is the first Indian biotech company to receive US funding for proprietary technologies
Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
November 29, 1978
Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated fun88官网 enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw